Effect of recombined human glucagon-like peptide-1 on body weight, blood glucose metabolism and β cell function and mass in GK rat

Fudan University Journal of Medical Sciences

Volumn 34, Issue 1, 2007, Pages 111-115

  Gu, Qian ^a   Gao, Xin ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

cell mass; GK rat; Glucagon like peptide 1

Indexed keywords

EID: 34248649332     PISSN: 16728467     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Gromada, J. Brock, B, Sxhmitz O, et al. GLucagon-like peptide-1; regulation of insulin secretion and therapeutic potential[J]. Basic & Clin Pharmacol & Toxicol, 2004, 95:252
2. Ce'cile T, Danielle B, Lacorne M, et al. Persistant persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4 [J]. Diabetes, 2002, 51:1443
3. Pospisilik JA, Stafford SG, Kang E, et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats[J]. Diabetes, 2002, 51: 943
4. Bidda R, Marianne O, Bulotta A, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice[J]. Am J Physiol Endocrinol Metab, 2002, 283:E745
5. Wang Y, Perfetti R, Nigel H G, et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats [J]. J Clin Invest, 1997, 99:2883
6. Chinese source
7. Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat[J]. Diabetes, 1998; 47:358
8. Szayna M, Doyle ME, Cahill CJ, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats [J]. Endocrinol, 2000, 141:1936
9. Scrocchi LA, Drucker DJ, Orskov C, et al. Effects of aging and a high fat diet on body weight and glucose control in GLP-1R-/-mice[J]. Endocrinol, 1998, 139:3127
10. Greig NH, Holloway HW, Ahren B, et al. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations [J]. Diabetologia, 1999, 42:45
11. Perfetti R, Zhou J, Maire E D, et al. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats[J]. Endocrinol, 2000, 141:4600
12. Ritzel R, Ørskov C, Holst JJ, et al. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1[7-36 amide] after subcutaneous injection in healthy volunteers, Doseresponse-relationships[J]. Diabetologia, 1995, 38:720
13. Nauck MA. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes[J]. Horm Metab Res, 2004, 36:852